Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07246265

Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care

Led by University Hospital, Tours · Updated on 2026-03-10

100

Participants Needed

6

Research Sites

130 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Background: Sickle cell disease is a genetic disorder of haemoglobin (which carries oxygen in red blood cells). The shape of sickle cell-patients' red blood cells is abnormal. Thus, red blood cells can be blocked in small vessels, responsible for painful crises due to a lack of downstream circulation. These crisis (acute vaso-occlusive crisis) require strong treatment based on morphine, and often require intensive care.However, treatment is often insufficiently effective. Patient can also experiment acute chest syndrome, a complication of vaso-occlusive crisis, which can be responsible for respiratory failure. In addition, patients with sickle cell disease frequently have kidney damage called sickle cell nephropathy, which in the early stages of the disease is responsible for renal hyperfiltration, meaning that the kidneys filter the blood more than necessary, with faster elimination of drugs. For example, it is known that higher doses of antibiotics must be used in these patients than in the general population for the same effectiveness. The hypothesis of the study is that morphine, a drug eliminated by kidneys, is underdosed in patients with sickle cell disease, which is responsible for the difficulties in achieving sufficient analgesia. Objective: To determine the glomerular filtration rate threshold for which it is necessary to prescribe higher doses of morphine in sickle cell patients with vaso-occlusive crisis. Methods: inclusion of 100 patients admitted to intensive care for an acute vaso-occlusive crisis or acute chest syndrome and receiving morphine. Within 24 hours of study inclusion, four morphine dosages will be performed, in parallel with a precise determination of the glomerular filtration rate by measuring the elimination rate of a tracer, 100% eliminated by the kidneys and injected at the start of the study. This tracer is iohexol, a contrast agent commonly used in radiology. Morphine underdosage will be interpretated regarding glomerular filtration rate. The effectiveness of analgesia and the amount of analgesics required will be also be analyzed. Outlook: At the end of this study, the investigators will be able to offer adapted doses of morphine for sickle cell patients in crisis, adapted to glomerular filtration rate, in the aim of personalizing analgesia.

CONDITIONS

Official Title

Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient is 18 years old or older
  • Known homozygous sickle cell disease SS, SC, S-beta+, or S-beta0
  • Currently admitted in an intensive care unit
  • Clinical diagnosis of vaso-occlusive crisis and/or acute chest syndrome
  • Receiving patient-controlled analgesia treatment with morphine
  • Provided consent for study participation or consent from a relative if patient is unable
  • Affiliated to social protection
Not Eligible

You will not qualify if you...

  • Previously included in this study during a prior hospital stay
  • Received iodinated contrast medium injection outside this study within 24 hours before inclusion or scheduled within 9 hours after iohexol injection
  • Known or suspected allergy to iohexol, or have thyrotoxicosis
  • Treated with morphine or substitution treatments like methadone or buprenorphine within the week before hospitalization
  • Have chronic liver disease such as cirrhosis affecting morphine metabolism
  • Any condition that contraindicates morphine use according to product guidelines
  • Under legal protection
  • Pregnant or breastfeeding women
  • Require extrarenal epuration within 24 hours of inclusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

CHRU de Tours

Tours, France, France, 37044

Actively Recruiting

2

Henri-Mondor

Créteil, France

Not Yet Recruiting

3

CH Le Mans

Le Mans, France, 72000

Not Yet Recruiting

4

CHU de Nantes

Nantes, France, 44093

Not Yet Recruiting

5

CHU d'Orléans

Orléans, France, 45067

Not Yet Recruiting

6

CHU de Rennes

Rennes, France

Not Yet Recruiting

Loading map...

Research Team

C

Charlotte SALMON-GANDONNIERE, MD

CONTACT

C

Coralie TAILLEBUIS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here